Skip to main content

Peer Review reports

From: Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Original Submission
15 Dec 2009 Submitted Original manuscript
9 Feb 2010 Reviewed Reviewer Report - Michael Retsky
22 Mar 2010 Reviewed Reviewer Report - Inge Marie Svane
8 Apr 2010 Author responded Author comments - Jitendra Mehrishi
Resubmission - Version 2
8 Apr 2010 Submitted Manuscript version 2
9 Apr 2010 Author responded Author comments - Jitendra Mehrishi
2 May 2010 Reviewed Reviewer Report - Inge Marie Svane
19 May 2010 Reviewed Reviewer Report - Michael Retsky
Resubmission - Version 3
9 Apr 2010 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
27 May 2010 Author responded Author comments - Jitendra Mehrishi
Resubmission - Version 6
27 May 2010 Submitted Manuscript version 6
Publishing
2 Jun 2010 Editorially accepted
2 Jun 2010 Article published 10.1186/1471-2407-10-251

You can find further information about peer review here.

Back to article page